TransMedics Group's (TMDX) "Hold" Rating Reiterated at Needham & Company LLC

Needham & Company LLC reaffirmed their hold rating on shares of TransMedics Group (NASDAQ:TMDX - Free Report) in a report released on Wednesday,Benzinga reports.

Other research analysts have also recently issued research reports about the stock. Canaccord Genuity Group restated a "buy" rating and set a $104.00 price target on shares of TransMedics Group in a research note on Tuesday, March 11th. JPMorgan Chase & Co. restated a "neutral" rating and set a $75.00 target price (down previously from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Piper Sandler lowered their price target on TransMedics Group from $110.00 to $90.00 and set an "overweight" rating on the stock in a research report on Wednesday, December 11th. Robert W. Baird cut their price objective on TransMedics Group from $150.00 to $120.00 and set an "outperform" rating for the company in a report on Wednesday, December 11th. Finally, Oppenheimer reaffirmed an "outperform" rating and issued a $125.00 target price on shares of TransMedics Group in a report on Tuesday, December 3rd. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $122.70.

Remove Ads

TransMedics Group Stock Performance

TMDX traded down $1.86 during trading on Wednesday, reaching $68.58. 612,338 shares of the company's stock were exchanged, compared to its average volume of 1,322,479. The company has a market capitalization of $2.31 billion, a P/E ratio of 72.96 and a beta of 2.12. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. The business has a 50 day moving average price of $69.11 and a 200 day moving average price of $88.08. TransMedics Group has a fifty-two week low of $55.00 and a fifty-two week high of $177.37.

Hedge Funds Weigh In On TransMedics Group

Several large investors have recently made changes to their positions in the company. Quarry LP lifted its position in TransMedics Group by 557.1% during the 3rd quarter. Quarry LP now owns 368 shares of the company's stock valued at $58,000 after purchasing an additional 312 shares during the period. National Bank of Canada FI lifted its holdings in TransMedics Group by 174.7% in the third quarter. National Bank of Canada FI now owns 412 shares of the company's stock valued at $65,000 after buying an additional 262 shares during the period. Atlas Capital Advisors Inc. bought a new position in TransMedics Group in the fourth quarter valued at approximately $31,000. Hager Investment Management Services LLC acquired a new stake in TransMedics Group during the 4th quarter worth $33,000. Finally, Sachetta LLC acquired a new position in shares of TransMedics Group in the 4th quarter valued at $40,000. Institutional investors and hedge funds own 99.67% of the company's stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.